IOVANCE BIO REVEALS $319M CASH RESERVE & STRONG REVENUE GROWTH

By Philip Seaworth • Friday, July 03 13:02 • Permanent Link

Iovance Biotherapeutics said cash stood at about $319 million as of March 31, 2026, and that amount is expected to fund operations into 2028. The company also set second-quarter 2026 revenue guidance at $86 million to $88 million and full-year 2026 revenue guidance at $350 million to $370 million.

The company said quarterly revenue was growing about 45% year over year in the first quarter of 2026. Gross margin in that quarter was 41%, which Iovance said was affected by non-recurring, one-time costs. It said efforts are underway to improve operating expenses, cost of sales and gross margin.

Commercially, Iovance said more than 90 treatment centers were authorized as of May 7, 2026, including centers in final stages of readiness or soon to be authorized. The company said more than 1,500 patients have now been treated with its commercial and clinical TIL products across the U.S., Canada and Australia.

For Amtagvi in previously treated advanced melanoma, Iovance highlighted 5-year follow-up data showing a 31.4% objective response rate, 19.7% overall survival, and a median duration of response of 36.5 months. Median follow-up in that dataset was 57.8 months.

The company also pointed to real-world data showing a 52% objective response rate in 23 patients, compared with 44% in 41 patients in another cohort. In the latter group, disease control rate was 73% and target lesions were reduced by 86% in a reported case.

Iovance said it has more than 90 authorized treatment centers in place, with one first Canadian center in Toronto. It also said the addressable patient population within 200 miles of an authorized treatment center is about 10,000.

The company’s pipeline includes TILVANCE-301 in frontline advanced melanoma, IOV-LUN-202 in post-chemo and anti-PD-1 advanced NSCLC, and IOV-SAR-201 in post-chemo advanced soft tissue sarcomas. It also listed IOV-MEL-202, IOV-END-201, IOV-GM1-201, IOV-IL2-101, IOV-GE1-201 and IOV-5001 across melanoma, endometrial cancer, colorectal cancer, breast cancer and next-generation TIL programs.

Iovance said its manufacturing facility in Philadelphia has capacity for up to 5,000 patients per year. Today the company's shares have moved 8.56% to a price of $4.31. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.